Calendar An icon of a desk calendar. Cancel An icon of a circle with a diagonal line across. Caret An icon of a block arrow pointing to the right. Email An icon of a paper envelope. Facebook An icon of the Facebook "f" mark. Google An icon of the Google "G" mark. Linked In An icon of the Linked In "in" mark. Logout An icon representing logout. Profile An icon that resembles human head and shoulders. Telephone An icon of a traditional telephone receiver. Tick An icon of a tick mark. Is Public An icon of a human eye and eyelashes. Is Not Public An icon of a human eye and eyelashes with a diagonal line through it. Pause Icon A two-lined pause icon for stopping interactions. Quote Mark A opening quote mark. Quote Mark A closing quote mark. Arrow An icon of an arrow. Folder An icon of a paper folder. Breaking An icon of an exclamation mark on a circular background. Camera An icon of a digital camera. Caret An icon of a caret arrow. Clock An icon of a clock face. Close An icon of the an X shape. Close Icon An icon used to represent where to interact to collapse or dismiss a component Comment An icon of a speech bubble. Comments An icon of a speech bubble, denoting user comments. Comments An icon of a speech bubble, denoting user comments. Ellipsis An icon of 3 horizontal dots. Envelope An icon of a paper envelope. Facebook An icon of a facebook f logo. Camera An icon of a digital camera. Home An icon of a house. Instagram An icon of the Instagram logo. LinkedIn An icon of the LinkedIn logo. Magnifying Glass An icon of a magnifying glass. Search Icon A magnifying glass icon that is used to represent the function of searching. Menu An icon of 3 horizontal lines. Hamburger Menu Icon An icon used to represent a collapsed menu. Next An icon of an arrow pointing to the right. Notice An explanation mark centred inside a circle. Previous An icon of an arrow pointing to the left. Rating An icon of a star. Tag An icon of a tag. Twitter An icon of the Twitter logo. Video Camera An icon of a video camera shape. Speech Bubble Icon A icon displaying a speech bubble WhatsApp An icon of the WhatsApp logo. Information An icon of an information logo. Plus A mathematical 'plus' symbol. Duration An icon indicating Time. Success Tick An icon of a green tick. Success Tick Timeout An icon of a greyed out success tick. Loading Spinner An icon of a loading spinner. Facebook Messenger An icon of the facebook messenger app logo. Facebook An icon of a facebook f logo. Facebook Messenger An icon of the Twitter app logo. LinkedIn An icon of the LinkedIn logo. WhatsApp Messenger An icon of the Whatsapp messenger app logo. Email An icon of an mail envelope. Copy link A decentered black square over a white square.

Outcome ‘extremely good’ as most patients cured first time

Outcome ‘extremely good’ as most patients cured first time

In the UK there are approximately three cases of Hodgkin lymphoma per 100,000 per year and in the western world it predominantly affects young adults with the peak age range being between 18 and 35.

In Grampian we see 15-20 new cases per year. You don’t tend to see it so often in the middle years but it reappears again in the over-60s as a second peak in the incidence.

It presents with painless, enlarged, lymph glands which tend to feel “rubbery”, most commonly in the upper part of the body such as the neck and the centre of the chest.

Some patients describe having so-called “B symptoms”, including loss of weight and drenching night sweats. Patients are divided into having early stage disease or advanced stage disease. The former are treated with a combination of two to four cycles of chemotherapy and radiotherapy while advanced stage patients are likely to be treated with six to eight cycles of chemotherapy. The key thing is that the outcome is extremely good and the majority of patients are cured first time round.

Additionally, the 20% to 30% of people who relapse also have a good outlook and can be cured with further cycles of more intensive chemotherapy, followed by stem cell transplantation in some patients.

A recently-developed therapy directly targeted at the Hodgkin cell, brentuximab vedotin, has also improved the outlook for multiply relapsed patients.